Human Abuse Potential: Pharmacy Considerations

Human Abuse Potential (HAP) studies demand a rigorous intersection of DEA compliance and clinical precision. At the heart of a successful trial lies a specialized on-site cGMP pharmacy capable of managing controlled reference drugs while ensuring seamless blinded dosing. Maintaining the study’s integrity often requires sophisticated over-encapsulation techniques to make investigational products and comparators indistinguishable, protecting the validity of subjective data.

Rigorous quality control and specialized dosing strategies are essential to mitigate risks associated with controlled substances. Prioritizing these pharmacy fundamentals ensures participant safety and high-fidelity data that stands up to regulatory scrutiny.